Atai Life Sciences Future Growth
Future criteria checks 2/6
Atai Life Sciences is forecast to grow earnings and revenue by 34.6% and 82.3% per annum respectively. EPS is expected to grow by 46.2% per annum. Return on equity is forecast to be -129.6% in 3 years.
Key information
34.6%
Earnings growth rate
46.2%
EPS growth rate
| Pharmaceuticals earnings growth | 21.6% |
| Revenue growth rate | 82.3% |
| Future return on equity | -129.6% |
| Analyst coverage | Good |
| Last updated | 18 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 0 | -138 | -148 | -143 | 6 |
| 12/31/2025 | 0 | -119 | -121 | -116 | 6 |
| 12/31/2024 | 1 | -129 | -85 | -84 | 6 |
| 9/30/2024 | 0 | -129 | -80 | -80 | N/A |
| 6/30/2024 | 0 | -58 | -79 | -79 | N/A |
| 3/31/2024 | 0 | -34 | -86 | -86 | N/A |
| 12/31/2023 | 0 | -40 | -85 | -84 | N/A |
| 9/30/2023 | 0 | -67 | -93 | -93 | N/A |
| 6/30/2023 | 0 | -145 | -104 | -102 | N/A |
| 3/31/2023 | 0 | -149 | -103 | -102 | N/A |
| 12/31/2022 | 0 | -152 | -105 | -104 | N/A |
| 9/30/2022 | 0 | -196 | -97 | -94 | N/A |
| 6/30/2022 | 1 | -194 | -96 | -95 | N/A |
| 3/31/2022 | 0 | -205 | -73 | -71 | N/A |
| 12/31/2021 | 20 | -168 | -65 | -63 | N/A |
| 9/30/2021 | 20 | -166 | -50 | -49 | N/A |
| 6/30/2021 | 20 | -218 | -27 | -26 | N/A |
| 3/31/2021 | 20 | -185 | -34 | -33 | N/A |
| 12/31/2020 | N/A | -170 | -21 | -21 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 9VC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 9VC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 9VC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 9VC's revenue (82.3% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: 9VC's revenue (82.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 9VC is forecast to be unprofitable in 3 years.